Prognostic roles of telomerase reverse transcriptase promoter mutation and 1p/19q co-deletion in newly-diagnosed O6-methylguanine-DNA methyltransferase promoter un-methylated/isocitrate dehydrogenase wild-type glioblastoma multiform

Q4 Medicine
Q. Lu, Xiwei Zhang, Yang Wang, Xiaofang Sheng, Xueyong Wu, Xiaobai Wei, Hongyuan Gao, Xiaofeng Yin, F. Xie, Yueming Zhu, Z. Jin, Zhenghua Zhang, Haimin Wei, Dan Li, R. Huang, Xiang-Yu Wang, F. Xiao
{"title":"Prognostic roles of telomerase reverse transcriptase promoter mutation and 1p/19q co-deletion in newly-diagnosed O6-methylguanine-DNA methyltransferase promoter un-methylated/isocitrate dehydrogenase wild-type glioblastoma multiform","authors":"Q. Lu, Xiwei Zhang, Yang Wang, Xiaofang Sheng, Xueyong Wu, Xiaobai Wei, Hongyuan Gao, Xiaofeng Yin, F. Xie, Yueming Zhu, Z. Jin, Zhenghua Zhang, Haimin Wei, Dan Li, R. Huang, Xiang-Yu Wang, F. Xiao","doi":"10.3760/CMA.J.ISSN.1671-8925.2019.09.004","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the prognostic values of telomerase reverse transcriptase promoter (TERTp) mutation and 1p/19q co-deletion in newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter un-methylated/isocitrate dehydrogenase (IDH) wild-type glioblastoma multiform (GBM). \n \n \nMethods \nA total of 82 patients pathologically newly-diagnosed MGMT promoter un-methylated/IDH wild-type GBM, admitted to our hospitals from March 2016 to November 2018, were included in this study. TERTp mutations (TERTp wild-type and TERTp mutation [C228 mutation and C250 mutation]) in GBM specimens were detected by PCR sequencing, 1p/19q co-deletion in GBM specimens was detected by fluorescence in situ hybridization (FISH), and clinical data, adverse reactions and prognoses of patients with different molecular typing were compared. \n \n \nResults \nThere were 33 patients in the TERTp wild type group with mean age of 48 years, and 49 patients in the TERTp mutation group with mean age of 59 years; the difference of age was significant (P 0.05). There were 8 patients with 1p/19q co-deletion and 74 patients without 1p/19q co-deletion; no significant differences in above clinical parameters were noted between the two groups. There were no statistically significant differences in the incidences of bone marrow suppression, digestive tract response and fatigue, disease progression rate, or survival rate between patients from TERTp wild type group and TERTp mutation group, and between patients with 1p/19q co-deletion and patients without 1p/19q co-deletion (P>0.05). No significant differences in above clinical parameters, disease progression rate, and survival rate were noted between patients with C228 mutation and C250 mutation (P>0.05). \n \n \nConclusion \nTERTp typing and 1p/19q co-deletion status do not have prognostic value in newly-diagnosed MGMT un-methylated/IDH wild-type GBM patients; patients with TERTp mutations have older age than wild-type patients; patients with C250 mutation trend to have higher survival rate than those with C228 mutation. \n \n \nKey words: \nGlioblastoma; O6-methylguanine-DNA methyltransferase; Isocitrate dehydrogenase; Telomerase reverse transcriptase promoter mutation and lp/19q co-deletion","PeriodicalId":10104,"journal":{"name":"中华神经医学杂志","volume":"77 1","pages":"896-903"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华神经医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1671-8925.2019.09.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To explore the prognostic values of telomerase reverse transcriptase promoter (TERTp) mutation and 1p/19q co-deletion in newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter un-methylated/isocitrate dehydrogenase (IDH) wild-type glioblastoma multiform (GBM). Methods A total of 82 patients pathologically newly-diagnosed MGMT promoter un-methylated/IDH wild-type GBM, admitted to our hospitals from March 2016 to November 2018, were included in this study. TERTp mutations (TERTp wild-type and TERTp mutation [C228 mutation and C250 mutation]) in GBM specimens were detected by PCR sequencing, 1p/19q co-deletion in GBM specimens was detected by fluorescence in situ hybridization (FISH), and clinical data, adverse reactions and prognoses of patients with different molecular typing were compared. Results There were 33 patients in the TERTp wild type group with mean age of 48 years, and 49 patients in the TERTp mutation group with mean age of 59 years; the difference of age was significant (P 0.05). There were 8 patients with 1p/19q co-deletion and 74 patients without 1p/19q co-deletion; no significant differences in above clinical parameters were noted between the two groups. There were no statistically significant differences in the incidences of bone marrow suppression, digestive tract response and fatigue, disease progression rate, or survival rate between patients from TERTp wild type group and TERTp mutation group, and between patients with 1p/19q co-deletion and patients without 1p/19q co-deletion (P>0.05). No significant differences in above clinical parameters, disease progression rate, and survival rate were noted between patients with C228 mutation and C250 mutation (P>0.05). Conclusion TERTp typing and 1p/19q co-deletion status do not have prognostic value in newly-diagnosed MGMT un-methylated/IDH wild-type GBM patients; patients with TERTp mutations have older age than wild-type patients; patients with C250 mutation trend to have higher survival rate than those with C228 mutation. Key words: Glioblastoma; O6-methylguanine-DNA methyltransferase; Isocitrate dehydrogenase; Telomerase reverse transcriptase promoter mutation and lp/19q co-deletion
端粒酶逆转录酶启动子突变和1p/19q共缺失在新诊断的o6 -甲基鸟嘌呤- dna甲基转移酶启动子非甲基化/异柠檬酸脱氢酶野生型多形性胶质母细胞瘤中的预后作用
目的探讨端粒酶逆转录酶启动子(TERTp)突变和1p/19q共缺失在新诊断的o6 -甲基鸟嘌呤- dna甲基转移酶(MGMT)启动子非甲基化/异柠檬酸脱氢酶(IDH)野生型多形性胶质母细胞瘤(GBM)中的预后价值。方法选取2016年3月至2018年11月我院收治的病理新诊断MGMT启动子未甲基化/IDH野生型GBM患者82例。采用PCR测序检测GBM标本中TERTp突变(TERTp野生型和TERTp突变[C228突变和C250突变]),采用荧光原位杂交(FISH)检测GBM标本中1p/19q共缺失,比较不同分子分型患者的临床资料、不良反应和预后。结果TERTp野生型组33例,平均年龄48岁;TERTp突变组49例,平均年龄59岁;年龄差异有统计学意义(p0.05)。1p/19q共缺失8例,非1p/19q共缺失74例;两组患者上述临床参数均无显著差异。TERTp野生型组与TERTp突变组、1p/19q共缺失组与非1p/19q共缺失组骨髓抑制发生率、消化道反应及疲劳发生率、疾病进展率、生存率比较,差异均无统计学意义(P>0.05)。C228突变与C250突变患者在上述临床参数、疾病进展率及生存率方面均无显著差异(P>0.05)。结论TERTp分型和1p/19q共缺失状态对新诊断的MGMT非甲基化/IDH野生型GBM患者无预后价值;TERTp突变患者比野生型患者年龄大;C250突变患者的生存率高于C228突变患者。关键词:胶质母细胞瘤;O6-methylguanine-DNA甲基转移酶;异柠檬酸脱氢酶;端粒酶逆转录酶启动子突变和lp/19q共缺失
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
中华神经医学杂志
中华神经医学杂志 Psychology-Neuropsychology and Physiological Psychology
CiteScore
0.30
自引率
0.00%
发文量
6272
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信